- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07827599
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants (Pearlstone)
A Phase III, Randomized, Double-blinded, Placebo-controlled Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis of Influenza Virus Infection in Chinese Participants
The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in participants who are household contacts (HHCs) of participants with influenza (index participants).
연구 개요
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Fastest response: use the inquiry form https://www.gene.com/contact-us/submit-medical-inquiry
연구 연락처 백업
- 이름: Roche Pharma (Schweiz) AG Reference Study ID Number: YV46459, https://forpatients.roche.com/
- 전화번호: 888-662-6728 (U.S. Only)
- 이메일: global-roche-genentech-trials@gene.com
연구 장소
-
-
-
Changde, 중국, DUMMY_VALUE
- 모병
- The First People's Hospital of Changde
-
Huizhou, 중국, 516001
- 모병
- Huizhou Central People's Hospital
-
Ningbo, 중국, 315000
- 모병
- Ningbo No.2 Hospital
-
Sanmenxia, 중국, DUMMY_VALUE
- 모병
- Sanmenxia Central Hospital
-
Shanghai, 중국, 200040
- 모병
- Huashan Hospital Affiliated to Fudan University
-
Xiamen, 중국, 361001
- 모병
- Xiamen Maternal and Child Health Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, 중국, 510280
- 모병
- Zhujiang Hospital, Southern Medical University
-
-
Sichuan
-
Mianyang, Sichuan, 중국, 621000
- 모병
- Mianyang Central Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Index Participants (Participants With Influenza Virus Infection):
- First participant in a household with influenza virus infection in the current influenza season
- Fewer than 6 HHCs
- Agreement by all household members to participate in the study and comply with the study protocol for the duration of the study
- Diagnosed as having influenza with positive rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) result
- Onset of symptoms within 48 hours or less at time of signing Informed Consent Form (ICF)/Assent Form
- PCR (-) or antigen test (-) for severe acute respiratory virus-coronavirus 2 (SARS-CoV-2) using point-of-care or local laboratory test
HHCs of Index Participants:
- Lived with the index participant for 48 hours or more prior to informed consent/assent
- Meet all the following criteria and are judged not to have influenza virus infection by the investigator: body temperature (tympanic) <37.5 degrees Celsius (°C); no influenza-like symptoms (cough, sore throat, headache, nasal discharge/nasal congestion, feverishness or chills, muscle or joint pain, or fatigue) at screening; negative RIDT or PCR result for influenza
- For participants 12 years of age or older, ability to evaluate influenza symptoms by using a participant influenza symptoms diary; For participants under 12 years of age, capability of parents/caregivers to evaluate influenza symptoms by using a participant influenza symptoms diary
- PCR (-) or antigen test (-) for SARS-CoV-2 using point-of-care or local laboratory test
Exclusion Criteria:
HHCs of Index Participants:
- Diagnosed with influenza during the current influenza season
- Unable to live with the index patient from screening until Day 10
- Live with a household member who has any influenza-like symptom(s) other than the index participant on the day of screening
- Live with household members other than the index participant who was diagnosed with or strongly suspected to have influenza during the current influenza season
- Have any underlying diseases requiring systemic (oral or injection), or nasal treatment of antipyretics/analgesics, corticosteroids, or immunosuppressive agents
- Immunocompromised
- Use of any medications with anti-influenza effect within 30 days prior to screening
- Known allergy and/or history of significant intolerance against baloxavir marboxil
- Exposure to an investigational drug within 30 days or 5 half-lives of the drug prior to screening, whichever is longer
Note: Other protocol-defined inclusion/exclusion criteria may apply
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Baloxavir Marboxil
HHCs will receive baloxavir marboxil according to their body weight as outlined in the protocol. |
Baloxavir marboxil will be administered to the HHCs as per the schedule specified in the protocol.
다른 이름들:
|
|
위약 비교기: Placebo
HHCs will receive baloxavir marboxil matching placebo according to their body weight as outlined in the protocol. |
Baloxavir marboxil matching placebo will be administered to the HHCs as per the schedule specified in the protocol. |
|
간섭 없음: No Intervention
Index participants will not receive any study treatment but will continue to receive SOC treatment for influenza, as per the local guidelines. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Percentage of Participants who are Infected With Influenza Virus (Reverse Transcription - Polymerase Chain Reaction [RT-PCR] Positive), and Present With Fever and at Least one Respiratory Symptom
기간: From Day 1 up to Day 10
|
From Day 1 up to Day 10
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Percentage of Participants who are Infected With Influenza Virus (RT-PCR Positive), and Present With Fever or at Least one Influenza Symptom (Respiratory or Systemic)
기간: From Day 1 up to Day 10
|
From Day 1 up to Day 10
|
|
Percentage of Participants who are Infected With Influenza Virus (RT-PCR Positive) Regardless of Body Temperature or Influenza Symptoms
기간: From Day 1 up to Day 10
|
From Day 1 up to Day 10
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: Up to Day 21
|
Up to Day 21
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Clinical Trials, Hoffmann-La Roche
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- YV46459
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .